Study: Adalimumab beneficial for Crohn’s disease patients

admin — Mon, 13 Oct 2008 07:52:43 +0000

Findings from recently held two studies reveal that adalimumab reduces the risk of hospitalization as well as major surgery in patients suffering from Crohn’s disease (CD). The year long phase 3 trial (named CHARM) found that adalimumab was effective in improving the condition of patients with Crohn’s disease. There was a reduction in hospitalizations by half. Moreover, majority of Crohn’s disease patients undergo surgery. The results of the trial showed surgeries related to CD were reduced by as much as 90% in patients receiving adalimumab as compared to those receiving placebo. This makes the drug a cost-effective solution to the disorder. The study received support in the form of industry grants from Abbott Laboratories.

FDA OKs Aloxi injection for postoperative nausea, vomiting

admin — Tue, 25 Mar 2008 15:24:45 +0000

The FDA has approved the Aloxi(R) (palonosetron hydrochloride) injection for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours after surgery. The injection has been developed by Eisai Corporation of North America, its U.S. subsidiary, MGI Pharma, and Helsinn Healthcare SA. Aloxi already had FDA approval, since 2003, for the prevention of acute and delayed nausea and vomiting associated with chemotherapy.

Surgical Product Guide » Pharmaceutical products

Study: Adalimumab beneficial for Crohn’s disease patients

FDA OKs Aloxi injection for postoperative nausea, vomiting